Akero Therapeutics, Inc.
AKRO
Rangering i aksjer
#3731
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Aksjekurs
$54.65
Sist synkronisert: 2025-12-09
Markedsverdi
$4.50B
Endring (1 dag)
0.00%
Endring (1 år)
1.58%
Land
US
Handel Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Inntekter for Akero Therapeutics, Inc. (AKRO)
Inntekter i Sep 2025 TTM: $-292.82M
Ifølge Akero Therapeutics, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-292.82M. I 2023 hadde selskapet et resultat på $-151.76M, en nedgang sammenlignet med resultatet i 2022, som var $-112.03M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Akero Therapeutics, Inc. fra 2017 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-292.82M | 16.17% |
| 2024 | $-252.06M | 66.09% |
| 2023 | $-151.76M | 35.46% |
| 2022 | $-112.03M | 11.17% |
| 2021 | $-100.78M | 27.23% |
| 2020 | $-79.21M | 81.02% |
| 2019 | $-43.76M | -46.45% |
| 2018 | $-81.71M | 1,690.40% |
| 2017 | $-4.56M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -1,901.41% |
US
|
|
| $-3.09B | 954.23% |
US
|
|
| $-4.02B | 1,271.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -766.16% |
NL
|
